A semaglutide mutant, fusion protein, and related products for pulmonary drug delivery
By optimizing and modifying somaglutide and binding to IgG1 Fc fragments, the formation of somaglutide-Fc fusion protein is solved, and the problems of short half-life and poor stability of somaglutide in clinical applications are achieved longer The half-life and better sugar-control and weight-reducing effect have become an effective long-term weight-reducing and sugar-controlling drug.
Patent Information
- Application Number
- CN202410781200.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-18
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-06-18
AI Technical Summary
In clinical applications, somaglutide has problems such as short half-life, poor stability, low receptor activity and large doses of administration, making it difficult to achieve the best effect of sugar control and weight loss.
By optimizing and modifying somaglutide, a somaglutide mutant and its fusion protein were designed, combining IgG1 Fc fragments to form somaglutide-Fc fusion proteins, and spray-drying was used to prepare dry powder inhalation preparations, which improved the drug stability and bioavailability.
It significantly prolongs the in vivo half-life of somaglutide, improves receptor activity, and achieves better sugar-control and weight loss effects, becoming an effective long-term weight loss and sugar-control drug.
Smart Images

Figure CN118344462B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of fusion proteins, and in particular to a semaglutide mutant, fusion protein and related products for pulmonary administration. Background Art
[0002] Diabetes mellitus is a global disease and one of the major threats to human health. Diabetes mellitus is divided into type 1 diabetes and type 2 diabetes. Insulin supplementation is the main treatment for type 1 diabetes. Type 2 diabetes mellitus (DM) is a disease that seriously endangers human health; type 2 diabetes mellitus refers to a metabolic disease in which the body lacks insulin or the utilization rate of insulin is reduced, resulting in a continuous increase in the patient's blood sugar. The patient often has abnormal lipid metabolism, and most patients are obese. Long-term exposure to high blood sugar and high fat in the body can lead to lesions in blood vessels and nerves, which in turn harms the heart, kidneys and other organs.
[0003] Recent studies have shown that insulin resistance and insufficient insulin secretion are characteristic pathological physiological changes of diabetes, and the interaction between the two ultimately leads to the occurrence of diabetes. In addition, insulin resistance is also involved in the occurrence and development of chronic complications of diabetes, such as cardiovascular complications and diabetic nephropathy, and is an important link between diabetes, hypertension, hyperlipidemia, and coronary heart disease.
[0004] Somatostatin is a new type of hypoglycemic and anti-obesity drug. Compared with other anti-diabetic drugs, it has the dual effects of hypoglycemic and weight loss. It is a new generation of GLP-1 analog developed by Novo Nordisk of Denmark and a long-acting GLP-1 preparation (weekly preparation). Semaglutide has a high homology with human GLP-1. It is based on the natural human GLP-1 (7-37) molecule, and is obtained by replacing the 8th amino acid (alanine replaced by α-aminobutyric acid) and the 34th amino acid (lysine replaced by arginine), and at the same time connecting the C18 fatty diacid side chain at the 26th lysine through a spacer. It can inhibit the secretion of growth hormone, insulin and glucagon, and has important endocrine regulatory functions. Among them, the regulation of insulin and glucagon by semaglutide significantly affects blood sugar stability, and thus it has been widely studied for its potential in the treatment of diabetes.
[0005] However, clinical trials have shown that semaglutide also has obvious shortcomings, mainly in the following aspects: first, the short half-life leads to frequent injections, which brings inconvenience to patients; second, the weight loss and blood sugar lowering effects are still limited, and there are still certain unmet clinical needs; finally, some problems with semaglutide, such as poor stability and low receptor activity, lead to large dosages, making it difficult to achieve the optimal effect of blood sugar control and weight loss.
[0006] Fusion protein drugs are one of the long-acting drugs. These fusion protein-based drugs have longer half-lives, minimal toxicity, high specificity, excellent targeting capabilities, and remarkable stability, leading to their rapid popularity in the biopharmaceutical industry. There are three main fusion partners for fusion protein-based drugs: Fc fragments, albumin, and transferrin. IgGFc fusion protein is a genetically engineered recombinant protein that combines a functional protein with specific biological activity into the IgG Fc fragment; the application of the Fc fragment is not limited to IgG, and studies have shown that IgA, IgE, and IgM can also be used as effective substitutes for IgG for therapeutic applications.
[0007] At the same time, the present invention prepares the dry powder inhalation preparation of the semaglutide mutant after the fusion protein by spray drying, and the dry powder inhalation preparation prepared by freeze spray drying effectively protects the activity of the drug while improving the stability of the drug, so that it can maintain long-term stability at room temperature. Compared with other administration methods, the dry powder inhalation preparation prepared by spray freeze drying has high bioavailability and can more fully exert its pharmacological effects in vivo. Summary of the invention
[0008] To solve the above problems, the inventors optimized and modified semaglutide, improved its stability, prolonged its half-life in the body, increased receptor activity, optimized the balance between receptors, and achieved the best effect of controlling sugar and reducing weight;
[0009] In the first aspect of the present invention, the present invention provides a semaglutide mutant. According to an embodiment of the present invention, the polypeptide has the following amino acid sequence:
[0010] His-Aib-EGTFTSDVSSYLEGQAAKVFIAWLVRERG (SEQ ID NO: 2);
[0011] His-Aib-EGTFTSQVSSYLEKQAAKEFIAWLVRGRG (SEQ ID NO:3);
[0012] The amino acid sequence shown in SEQ ID NO: 2-3 has a strong in vitro biological activity against GLP-1;
[0013] The present invention proposes a fusion protein. According to an embodiment of the present invention, the fusion protein includes the above-mentioned polypeptide, a connecting peptide and an IgG1 Fc fragment, and the connecting peptide is arranged between the head and the tail of the polypeptide and the IgG 1Fc fragment. The fusion protein according to the embodiment of the present invention has a good hypoglycemic and weight-reducing effect and a long half-life in vivo, and is an effective long-acting weight-reducing and sugar-controlling drug.
[0014] According to an embodiment of the present invention, the N-terminus of the connecting peptide is connected to the C-terminus of the polypeptide, and the C-terminus of the connecting peptide is connected to the N-terminus of the IgG1 Fc fragment;
[0015] The present invention provides a nucleic acid, and according to an embodiment of the present invention, the nucleic acid encodes the above-mentioned fusion protein;
[0016] The present invention provides a protein preparation, which, according to an embodiment of the present invention, comprises the above-mentioned polypeptide or the above-mentioned fusion protein.
[0017] The protein preparation according to the embodiment of the present invention is an effective long-acting weight loss and sugar control drug. The present invention proposes the use of the above polypeptide or the above fusion protein in the preparation of a drug for treating or preventing metabolic diseases.
[0018] The metabolic disease includes at least one selected from non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetes, and obesity.
[0019] According to an embodiment of the present invention, a dry powder preparation is provided, comprising semaglutide-Fc fusion protein.
[0020] Compared with the prior art, the present invention has the following advantages and beneficial effects:
[0021] Compared with semaglutide, the semaglutide mutant polypeptide of the present invention has significant affinity activity and can significantly activate GLP-1 receptor cells; at the same time, the semaglutide mutant-IgG1 Fc fusion protein has different mutation sites from the existing disclosed polypeptides or fusion proteins, has good blood sugar lowering and weight loss effects, and has a long half-life in the body. It is a more effective long-acting weight loss and sugar control drug. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 The experimental results of the effect of the fusion protein according to the embodiment of the present invention on glucose tolerance of DIO mice 24 hours after administration.
[0023] Figure 2 The experimental results of the effect of the fusion protein according to the embodiment of the present invention on glucose tolerance of DIO mice 48 hours after administration.
[0024] Figure 3 The experimental results of the effect of the fusion protein according to the embodiment of the present invention on glucose tolerance in DIO mice 72 hours after administration.
[0025] Figure 4 The experimental results of the effect of the fusion protein according to the embodiment of the present invention on glucose tolerance in DIO mice 96 hours after administration.
[0026] Figure 5Experimental results of the effect of the fusion protein on the weight change of DIO mice according to the embodiments of the present invention.
[0027] Figure 6 Som-C07-IgG1Fc-Micro / Som-C08-IgG1Fc-Micro dry powder formulation was administered to dogs by dry powder inhalation. DETAILED DESCRIPTION
[0028] The methods and applications of the present invention have been described through preferred embodiments. Relevant personnel can obviously modify or appropriately change and combine the methods and applications herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0029] Definition of terms
[0030] The terms "protein" and "polypeptide" are used interchangeably and, in their broadest sense, refer to a compound of two or more subunit amino acids, amino acid analogs or peptide mimetics. The subunits may be linked by peptide bonds. In another embodiment, the subunits may be linked by other bonds, such as ester, ether, amino, etc. A protein or polypeptide must contain at least two amino acids and there is no limit to the maximum number of amino acids that can constitute a protein or peptide sequence. As used herein, the term "amino acid" refers to natural and / or non-natural or synthetic amino acids, including D and L optical isomers of amino acids, such as glycine and D and L optical isomers, amino acid analogs and peptide mimetics.
[0031] The term "semaglutide precursor" refers to the portion of the semaglutide polypeptide that does not contain the dipeptide His-Aib-, specifically the sequence of which is EGTFTSDVSSYLEGQAAKEFIAWLVRGRG;
[0032] The "Fc fragment" described herein is composed of the hinge region, CH2 and CH3 constant region structures of the antibody. Antibodies contain two functionally independent parts, a variable domain called "Fab" that binds to the antigen and a constant domain called "Fc" that participates in effector functions (such as complement activation and attack by phagocytes);
[0033] When forming the fusion protein of the present invention, a linker or connecting peptide can be used but is not required. The G-rich polypeptide of the present invention can be selected from (G) 3-S (i.e., "GGGS"), (G) 4-S (i.e., "GGGGS") and (G) 5-S (i.e., "GGGGGS"). In some embodiments, the connecting peptide comprises GGGGSGGGGS (SEQ ID NO: 8), GGGGSGGGGSGGGGS (SEQ ID NO: 6) or GGGGSGGGGSGGGGSA (SEQ ID NO: 7). The linkers described herein are exemplary, and the linkers of the present invention can be much longer linkers and linkers comprising other residues. The linkers of the present invention can also be non-peptide linkers.
[0034] Example 1 Preparation method of semaglutide and its mutants:
[0035] The biological fermentation method for preparing semaglutide is as follows:
[0036] The target gene LG1 with a stop codon at the C-terminus and adjacent to the bovine enterokinase site at the N-terminus of the Lys26Arg34GLP-1(9-37) gene was amplified by PCR, and then connected to the pET31b(+) vector to construct a recombinant fusion expression vector pET31b(+)-LG1 expressing KSI-Arg34GLP-1(9-37), and transformed into (Escherichiacoli) BL21(DE3) to construct an expression engineering strain. IPTG was used to induce the fermentation cells to express the target protein, and the fermentation cells were ultrasonically broken and washed to obtain inclusion body proteins. After the inclusion body protein was denatured and renatured, it was initially purified by strong anion exchange chromatography to obtain a fusion protein with high purity. The fusion protein was further cleaved by enterokinase and purified by reverse phase chromatography to obtain the precursor molecule of semaglutide Arg34GLP-1 (9-37), which was then connected to the His-Aib short peptide to obtain the semaglutide molecule. The Som-C07 and Som-C08 mutants were prepared by the same method. The specific process is as follows: 1. Vector construction and primer synthesis: pET31b was used as the expression vector and BL21 (DE3) was used as the host. The specific steps for preparing the polypeptide are as follows: design primers, which serve as templates for each other to amplify the mutant polypeptide gene fragment; construct a recombinant expression vector: the fusion gene fragment was cloned into the prokaryotic expression vector pET-28a, transformed into Escherichia coli BL21 (DE3), and the recombinant was selected. The recombinant expression plasmid sample was sent to Guangzhou GenScript Biotechnology Co., Ltd. for sequencing verification. 2. Expression purification: The constructed BL21 (DE3) strain was cultured in LB, and kanamycin (kanamycin) with a final concentration of 50 μg / mL was added. After culture, IPTG was used to induce expression for 5 hours. Take the centrifuged bacteria, dissolve them with equilibrium buffer (20mM Tris-HCl, pH8.0, 150mM NaCl), break the bacteria with an ultrasonicator, and use the supernatant after centrifugation for fusion protein purification. Purify by strong anion exchange chromatography, and elute with elution buffer (20mM Tris-HCl, pH8.0, 150mM NaCl) to obtain the fusion protein. 3. Fusion protease cleavage: After diluting the protein solution with equilibrium buffer, add enterokinase at a ratio of 50:1 of protein: enterokinase, and digest at room temperature for 1.5h.4. Purification and connection of polypeptide: The polypeptide obtained above (1.0 g) was completely dissolved in 0.05 mol / L potassium dihydrogen phosphate aqueous solution (pH 6.5) to prepare a 20 mg / ml solution, which was purified after filtration through a 0.22 µm membrane [separation conditions: chromatographic column Sunfire C18 preparative column (19 mm × 250 mm, 10 µm); mobile phase A: potassium dihydrogen phosphate aqueous solution (pH 6.5), B: acetonitrile, gradient elution (0→5 min: A90%; 5→10 min: A90%~65%; 10→75 min: A65%~60%); detection wavelength 215 nm; flow rate 10.0 ml / min]. The main peak was collected for analysis, and samples with a purity greater than 97% were combined. The acetonitrile was evaporated under reduced pressure at 35°C, and the mixture was freeze-dried to obtain a white solid compound. Then, the His-Aib short peptide was connected, and the separated product was analyzed by liquid chromatography-mass spectrometry to obtain semaglutide mutants Som-C07 and Som-C08. The results are shown in Table 1.
[0037] Table 1: Amino acid sequences of semaglutide and its mutants and their sample names
[0038]
[0039] Example 2 Preparation of Som-C07-IgG1Fc and Som-C08-IgG1Fc fusion proteins:
[0040] Using molecular cloning methods:
[0041] The precursor sequences of Som-C07 and Som-C08 (without the dipeptide His-Aib-) were fused with the IgG1-Fc mutant (SEQ ID NO: 5) with a connecting peptide (SEQ ID NO: 4), and the obtained sequences were double-digested and inserted into the same restriction sites of the mammalian cell expression vector to construct a series of mutant vectors. After sequencing verification, the plasmid vectors were extracted with an endotoxin-free plasmid extraction kit (OMEGA) and stored at -20°C. Chinese hamster ovary (CHO) cells were resuscitated and subcultured to a density of about 6×10 6Cells were collected for transfection when the concentration of 1 μg / mL was 1 μg / mL, and ExpiCHOFectamineTM CHOTransfection Kit (ThermoFisher Scientific) was used, with a final concentration of 1 μg / mL. Enhancers and other reagents were added on the second day of transfection to maintain the growth of transfected cells, and the cell culture fluid was harvested when the cell viability dropped to about 80%; the cell culture fluid was centrifuged to collect the supernatant, and the residual cell debris was removed by filtration with a 0.22 μm filter membrane. The collected cell culture fluid was purified using a Protein A chromatography column, the target peak was collected, and then further purified by ion exchange chromatography, and the protein was finally eluted and collected with 0.02 M PBS. The sample was detected by 12% SDS-PAGE electrophoresis, and the electrophoresis pattern showed a single band. The precise molecular weight of the fusion protein was determined by mass spectrometry, which was basically consistent with the theoretical molecular weight, and then the His-Aib short peptide was connected, and the separated product was analyzed by liquid chromatography-mass spectrometry to obtain the amino acid sequence of the semaglutide-Fc fusion protein and the corresponding polypeptide sample name as shown in Table 2.
[0042] Table 2: Amino acid sequences of semaglutide-Fc fusion protein, IgG1-Fc mutant and connecting peptide
[0043]
[0044] Example 3 Determination of in vitro activity of polypeptides:
[0045] The Som, Som-C07, Som-C08, benaglutide, exenatide, liraglutide, Som-C07-IgG1Fc fusion protein and Som-C08-IgG1Fc fusion protein prepared by expression examples 1-2 were respectively acted on HEK293 cells expressing GLP-1R, and the specific operations were as follows: 1. The gene GLP-1R was optimized and conventionally synthesized at GenScript, and the gene was cloned into the vector pUC57-Amp to prepare mini-scale recombinant plasmid DNA and puncture bacteria containing the recombinant plasmid; 2. The pUC57-GLP-1R recombinant plasmid DNA was double-digested with HindIII and EcoR I, and the pUC57-GLP-1R was double-digested with HindIII and XhoI. After the digestion product was subjected to 1% agarose gel electrophoresis, the target band was cut out with a clean blade, and the target fragment was recovered using a gel recovery kit; 3. The target fragment digestion recovery product and the vector plasmid pcDNA3.1 fragment were subjected to T4 After ligase connection, transform DH5α competent cells, spread plates to isolate single colonies, pick transformants for expansion and sequencing verification; after PCR verification and enzyme verification, use pvuI restriction endonuclease for linearization. Finally, use ethanol precipitation to recover the plasmid. 4 Use Lipofectamine 3000 liposome transfection method to transfect the recovered linearized plasmid into HEK293 cells, add G418 to screen to obtain mixed strains, perform limiting dilution separation to obtain single clones, and perform activity detection verification.5. Use a cAMP detection kit (Cisbio, 62AM6PEC) to detect cAMP produced by receptor cells according to the steps described in the operating instructions. The specific steps are as follows: 1) Prepare Assay buffer: Take complete culture medium (DMEM medium + 10% FBS), add 4 / 1000 of 500mM IBMX mother solution, cAMP-d2 working solution and anti-cAMP-crytate working solution according to the instructions of the kit; 2) Dilute the samples Som, Som-C07, Som-C08, benaglutide, exenatide, liraglutide, Som-C07-IgG1Fc fusion protein and Som-C08-IgG1Fc fusion protein, and the positive control human GLP-1 to an initial concentration of 500nM mother solution, and then add 20μL to 80μL Assay Buffer (diluted 5 times) was diluted step by step, including the mother solution for a total of 8 compound gradients; 3) The samples to be tested and the gradient dilutions of the positive control were added to the 384-well plate of the corresponding cells, 5 μL per well (the same concentration of samples was repeated in 2 replicates); Negative control: 10 μL assay buffer / well, 3 wells were set for each 384-well plate, covered with a white sealing film, placed in a 37°C constant temperature incubator, and taken out after half an hour; Before use, the cAMP-d2 working solution and anti-cAMP-crytate were diluted with the lysis buffer in the Hi-range kit; 4) The working solution was diluted 20 times and mixed evenly in a 1:1 ratio to prepare a mixed solution of cAMP detection reagent, 10 μL of the mixed solution of cAMP detection reagent was added to each well of the sample group, and 5 μL of the mixed solution of the negative control was added to each well lysis buffer and 5 μL of diluted anti-cAMP-crytate working solution, cover with a white lid, and place at room temperature away from light for 1 hour; detect the fluorescence values at 665nm and 620nm in a multifunctional microplate reader; establish a dose-effect curve, calculate the EC50 value, and compare them with each other. The specific results are shown in Table 3.
[0046] Table 3: In vitro activity EC50 values of peptides
[0047]
[0048] As can be seen from Table 3, the EC50 values of all samples are below nanomolar, which can significantly activate GLP-1 receptor cells. Among them, the biological activity of Som-C07 and Som-C08 mutants is stronger, and its effect is much higher than that of benaglutide, exenatide, liraglutide and semaglutide. In addition, the biological activity of Som-C07-IgG1Fc (0.01673±0.00612) and Som-C08-IgG1Fc (0.01573±0.00513) fusion proteins is the strongest, which is much higher than that of benaglutide, exenatide, semaglutide control substances and their monomers Som-C07 and Som-C08.
[0049] Example 4 Glucose tolerance activity of fusion protein
[0050] The fusion proteins Som-C07-IgG1Fc and Som-C08-IgG1Fc prepared in Example 2 were prepared for use. Eighteen C57BL / 6 mice were randomly divided into three groups according to body weight, with 6 mice in each group. They were numbered one by one and administered with semaglutide (dose 320 μg·kg-1), Som-C07-IgG1Fc (dose 320 μg·kg-1), Som-C08-IgG1Fc (dose 320 μg·kg-1) and blank control (10 mmol·L-1 phosphate buffer, pH 7.4), respectively. 0.2 mL of 40% glucose was injected intraperitoneally at 24, 48, 72, and 96 h after administration, and blood was collected from the tail vein before and 15, 30, and 60 min after injection. The blood glucose level was measured with a blood glucose meter to evaluate the glucose tolerance of the mice after administration. The blood glucose concentration-time curve was drawn according to the blood glucose values measured at different time points as shown in FIG. Figure 1-4 shown.
[0051] Figure 1-4 The results showed that compared with the blank control and semaglutide, the fusion proteins Som-C07-IgG1Fc and Som-C08-IgG1Fc still had significant hypoglycemic effects when glucose was injected 15 min and 30 min after 24, 48, 72, and 96 h after administration, and in the range of 24-72 h after administration, the hypoglycemic activity of the fusion proteins Som-C07-IgG1Fc and Som-C08-IgG1Fc was significantly stronger than that of semaglutide. Even after 96 h, the fusion proteins Som-C07-IgG1Fc and Som-C08-IgG1Fc still had hypoglycemic activity comparable to that of semaglutide.
[0052] Example 5 Body weight reduction activity of fusion protein
[0053] The fusion proteins Som-C07-IgG1Fc and Som-C08-IgG1Fc prepared in Example 2 were prepared for use. Six-week-old C57BL / 6 mice were selected and fed with a high-fat diet for 20 weeks. They were divided into four groups according to their body weight (Model, semaglutide 5nmol / kg, Som-C07-IgG1Fc 6nmol / kg, Som-C08-IgG1Fc 6nmol / kg). Drug administration began in the 21st week (the model group was given the corresponding phosphate buffer), semaglutide was administered once a day, and the remaining groups were administered twice a week for a total of 4 weeks. The animals were weighed before each administration. An IPGTT experiment was performed in the 4th week of administration. The effect of the fusion protein on the body weight of mice is shown in the figure. Figure 5 shown.
[0054] Figure 5 The results showed that semaglutide, Som-C07-IgG1Fc and Som-C08-IgG1Fc all had a significant effect on reducing the body weight of DIO mice, and the body weight reducing effects of Som-C07-IgG1Fc and Som-C08-IgG1Fc were better than semaglutide.
[0055] Example 6 Preparation of Semaglutide-Fc Fusion Protein Freeze-Spray-Drying Inhalation Dry Powder Formulation
[0056] The semaglutide-Fc fusion protein prepared in Example 5 was first homogenized at 14000 r / min and 4°C for 2 min to remove impurities, and then subjected to high-speed refrigerated centrifugation (9000 r / min, 4°C, 20 min). The supernatant was taken and mixed with DSPC:FDKP=5:1 (w / w) to form a prescription. PFOB (20-60%) was used as the oil phase and stirred at 8000 rpm by a homogenizer for 5 min. After freeze-drying, the fusion protein freeze-dried powder preparation Som-C07-IgG1Fc-Micro / Som-C08-IgG1Fc-Micro was obtained. The spray drying conditions were as follows: ASP (aspiration rate): 100%; inlet flow rate: 3 ml / min; air flow meter: 40 mm; nozzle size: 1.4 mm. The emulsion was sprayed into a spray cooling tower at -60°C, and then transferred to -40°C and 0.01 mbar for freeze drying (Scanvac, CoolSafe 100-9 Pro freeze dryer). It was used for the activity determination of active peptides.
[0057] Example 7 Pulmonary inhalation administration of semaglutide-Fc fusion protein lyophilized powder formulation
[0058] Administration of a frozen spray dry powder inhalation formulation of semaglutide-Fc fusion protein was demonstrated in dogs. Beagles were anesthetized and placed on a ventilator. The respiratory rate was maintained at 85% of the pre-anesthesia respiratory rate. 5 mg of the compressed Som-C07-IgG1Fc-Micro / Som-C08-IgG1Fc-Micro lyophilized powder formulation prepared in Example 6 was administered to the dogs using an Aerolizer dry powder inhaler. Figure 6 The results showed that a significant reduction in blood glucose was observed within 10 to 15 minutes after pulmonary administration of Som-C07-IgG1Fc-Micro and Som-C08-IgG1Fc-Micro semaglutide-Fc fusion protein lyophilized powder formulations, and the low blood glucose concentration was maintained for more than 4 hours before the dogs were given oral carbohydrate feed.
[0059] The above-mentioned embodiments only express several implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present application, and these all belong to the protection scope of the present application. Therefore, the protection scope of the patent of the present application shall be subject to the attached claims.
Claims
1. A semaglutide mutant for pulmonary inhalation administration, It is characterized in that The amino acid sequence of the semaglutide mutant is shown in SEQ ID NO: 2 or SEQ ID NO:
3.
2. A fusion protein for pulmonary administration, It is characterized in that include: The semaglutide mutant, connecting peptide and IgG1-Fc fragment according to claim 1, wherein the connecting peptide is arranged between the head and tail of the semaglutide mutant and the IgG1-Fc fragment.
3. The fusion protein according to claim 2, It is characterized in that The connecting peptide consists of the amino acid sequence shown in SEQ ID NO:4; and the IgG1-Fc fragment consists of the amino acid sequence shown in SEQ ID NO:
6.
4. The fusion protein according to claim 2 or 3, It is characterized in that The fusion protein consists of the amino acid sequence shown in any one of SEQ ID NOs: 7-8.
5. A freeze-dried powder inhalation preparation for pulmonary administration, Features The fusion protein as claimed in claim 3 or 4 is prepared by spray drying with DSPC and fumaryl diketopiperazine (FDKP) as main inhalation particle skeleton excipients.
6. a nucleic acid, It is characterized in that The nucleic acid encodes the semaglutide mutant according to claim 1 or the fusion protein according to any one of claims 2 to 4.
7. A recombinant cell, It is characterized in that Expressing the semaglutide mutant according to claim 1 or the fusion protein according to any one of claims 2 to 4, or containing the nucleic acid according to claim 6.
8. A pharmaceutical composition, It is characterized in that It includes the semaglutide mutant according to claim 1 or the fusion protein according to any one of claims 2 to 4.
9. Use of the semaglutide mutant according to claim 1, the fusion protein according to any one of claims 2 to 4, or the lyophilized powder inhalation preparation according to claim 5 in the preparation of a medicament for treating or preventing a metabolic disease, wherein the metabolic disease is selected from at least one of diabetes and obesity.
